Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after Bristol Myers Squibb BMY ...

Morgan Stanley lowered the firm’s price target on Arvinas (ARVN) to $12 from $48 and keeps an Equal Weight rating on the shares after the ...

Guggenheim analyst Michael Schmidt lowered the firm’s price target on Arvinas (ARVN) to $32 from $57 and keeps a Buy rating on the shares after ...

Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with ER+ ...

Arvinas (NASDAQ:ARVN – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports.

Arvinas (NASDAQ:ARVN – Get Free Report) was downgraded by analysts at Oppenheimer from an “outperform” rating to a “market perform” rating in a research report issued on Tuesday, Marketbeat Ratings ...

Fintel reports that on March 12, 2025, Wedbush downgraded their outlook for Arvinas (NasdaqGS:ARVN) from Outperform to ...

Susquehanna cut Teradyne, Inc. TER price target from $165 to $155. Susquehanna analyst Mehdi Hosseini maintained a Positive ...

Arvinas (ARVN) stock faces a downgrade after underwhelming trial data for breast cancer drug vepdegestrant developed with ...